Geovax Labs Inc. (GOVX) Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

Go back to Geovax Labs Inc. (GOVX) Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

GeoVax Expands Immuno-Oncology Pipeline with Acquisition of Clinical-Stage Cancer Program

September 28, 2021 4:00 PM EDT

License of Gedeptin® Adds Orphan Drug Clinical Program for Treatment of Advanced Head and Neck Cancers

ATLANTA, GA, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that it has entered into an Assignment and License Agreement (the License) with PNP Therapeutics, Inc.... More